208 related articles for article (PubMed ID: 31569719)
1. Treatment of Advanced Hepatocellular Carcinoma with Somatostatin Analogues: A Review of the Literature.
Reynaert H; Colle I
Int J Mol Sci; 2019 Sep; 20(19):. PubMed ID: 31569719
[TBL] [Abstract][Full Text] [Related]
2. Somatostatin receptor expression in hepatocellular carcinoma: prognostic and therapeutic considerations.
Abdel-Rahman O; Lamarca A; Valle JW; Hubner RA
Endocr Relat Cancer; 2014; 21(6):R485-93. PubMed ID: 25336571
[TBL] [Abstract][Full Text] [Related]
3. Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study.
Kouroumalis E; Skordilis P; Thermos K; Vasilaki A; Moschandrea J; Manousos ON
Gut; 1998 Mar; 42(3):442-7. PubMed ID: 9577356
[TBL] [Abstract][Full Text] [Related]
4. The role of somatostatin analogs in the management of hepatocellular carcinoma.
D'Agostino L; Manguso F; Pivonello R; Colao A
J Endocrinol Invest; 2003; 26(8 Suppl):131-3. PubMed ID: 15233229
[No Abstract] [Full Text] [Related]
5. Somatostatin analogues in advanced hepatocellular carcinoma: an updated systematic review and meta-analysis of randomized controlled trials.
Ji XQ; Ruan XJ; Chen H; Chen G; Li SY; Yu B
Med Sci Monit; 2011 Aug; 17(8):RA169-176. PubMed ID: 21804474
[TBL] [Abstract][Full Text] [Related]
6. [Somatostatin analogue (octreotide)].
Sano K; Makuuchi M
Nihon Rinsho; 2001 Oct; 59 Suppl 6():674-7. PubMed ID: 11762035
[No Abstract] [Full Text] [Related]
7. Somatostatin receptor expression, tumour response, and quality of life in patients with advanced hepatocellular carcinoma treated with long-acting octreotide.
Cebon J; Findlay M; Hargreaves C; Stockler M; Thompson P; Boyer M; Roberts S; Poon A; Scott AM; Kalff V; Garas G; Dowling A; Crawford D; Ring J; Basser R; Strickland A; Macdonald G; Green M; Nowak A; Dickman B; Dhillon H; Gebski V;
Br J Cancer; 2006 Oct; 95(7):853-61. PubMed ID: 16953241
[TBL] [Abstract][Full Text] [Related]
8. Somatostatin and hepatocellular carcinoma.
Kapadia CR
Gastroenterology; 1998 Nov; 115(5):1298-9. PubMed ID: 9797392
[No Abstract] [Full Text] [Related]
9. Treatment of hepatocellular carcinoma with long acting somatostatin analogues.
Samonakis DN; Moschandreas J; Arnaoutis T; Skordilis P; Leontidis C; Vafiades I; Kouroumalis E
Oncol Rep; 2002; 9(4):903-7. PubMed ID: 12066229
[TBL] [Abstract][Full Text] [Related]
10. Octreotide in hepatocellular carcinoma.
Shouval D
Gut; 1998 Mar; 42(3):316-7. PubMed ID: 9577332
[No Abstract] [Full Text] [Related]
11. Somatostatin analogs and hepatocellular carcinoma: Not dead yet?
Raftery L; O'Neil BH
Cancer Biol Ther; 2009 Nov; 8(21):2040-1. PubMed ID: 19823044
[No Abstract] [Full Text] [Related]
12. Mechanisms of action and resistance of somatostatin analogues for the treatment of hepatocellular carcinoma: a message not well taken.
Samonakis DN; Notas G; Christodoulakis N; Kouroumalis EA
Dig Dis Sci; 2008 Sep; 53(9):2359-65. PubMed ID: 18273705
[TBL] [Abstract][Full Text] [Related]
13. Successful treatment of an advanced hepatocellular carcinoma with the long-acting somatostatin analog lanreotide.
Raderer M; Hejna MH; Kurtaran A; Kornek GV; Valencak JB; Oberhuber G; Vorbeck F; Virgolini I; Scheithauer W
Am J Gastroenterol; 1999 Jan; 94(1):278-9. PubMed ID: 9934776
[TBL] [Abstract][Full Text] [Related]
14. Cortistatin production by HepG2 human hepatocellular carcinoma cell line and distribution of somatostatin receptors.
Notas G; Kolios G; Mastrodimou N; Kampa M; Vasilaki A; Xidakis C; Castanas E; Thermos K; Kouroumalis E
J Hepatol; 2004 May; 40(5):792-8. PubMed ID: 15094227
[TBL] [Abstract][Full Text] [Related]
15. The clinical role of somatostatin analogues as antineoplastic agents: much ado about nothing?
Hejna M; Schmidinger M; Raderer M
Ann Oncol; 2002 May; 13(5):653-68. PubMed ID: 12075733
[TBL] [Abstract][Full Text] [Related]
16. Antitumoral and Anti-inflammatory Roles of Somatostatin and Its Analogs in Hepatocellular Carcinoma.
Periferakis A; Tsigas G; Periferakis AT; Badarau IA; Scheau AE; Tampa M; Georgescu SR; Didilescu AC; Scheau C; Caruntu C
Anal Cell Pathol (Amst); 2021; 2021():1840069. PubMed ID: 34873567
[TBL] [Abstract][Full Text] [Related]
17. Octreotide for cancer of the liver and biliary tree.
Kouroumalis EA
Chemotherapy; 2001; 47 Suppl 2():150-61. PubMed ID: 11275708
[TBL] [Abstract][Full Text] [Related]
18. Octreotide and hepatocellular carcinoma.
Farinati F; Sergio A; Baldan A; Zucchetta P; Corleto VD
Br J Cancer; 2007 Jun; 96(11):1778-9. PubMed ID: 17505506
[No Abstract] [Full Text] [Related]
19. Hepatocellular carcinoma and octreotide: treatment results in prospectively assigned patients with advanced tumor and cirrhosis stage.
Plentz RR; Tillmann HL; Kubicka S; Bleck JS; Gebel M; Manns MP; Rudolph KL
J Gastroenterol Hepatol; 2005 Sep; 20(9):1422-8. PubMed ID: 16105131
[TBL] [Abstract][Full Text] [Related]
20. [A therapeutic study of hepatocellular carcinoma using octreotide (HECTOR). Hepatocellular Carcinoma: Treatment with Octreotide].
Allgaier HP; Becker G; Blum HE
Dtsch Med Wochenschr; 2000 Mar; 125(11):320. PubMed ID: 10761474
[No Abstract] [Full Text] [Related]
[Next] [New Search]
